Chiasma to Report Third Quarter 2020 Results on November 5
29 oct. 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
Chiasma Announces Planned Transition of Former CEO
01 oct. 2020 07h00 HE
|
Chiasma
NEEDHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
Chiasma to Participate in Two September Investor Conferences
08 sept. 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly
31 août 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism
17 août 2020 08h00 HE
|
Chiasma
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness
10 août 2020 16h05 HE
|
Chiasma
MYCAPSSA® U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarter Company to host conference call today, August...
Chiasma to Report Second Quarter 2020 Results on August 10
03 août 2020 16h01 HE
|
Chiasma
NEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly
27 juil. 2020 16h01 HE
|
Chiasma
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was...
Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants
01 juil. 2020 09h05 HE
|
Chiasma
NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its...
Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
30 juin 2020 16h30 HE
|
Chiasma
NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its...